Related Experiment Video
Updated: Feb 5, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
ERα is a negative regulator of PD-L1 gene transcription in breast cancer
Lu Liu1, Yinghui Shen1, Xuguo Zhu1
1Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Abstract:
The programmed death-ligand 1 (PD-L1) expression by tumors results in potent antitumor immune suppression through binding to programmed death-1 (PD-1) on T cells and subsequent inhibition of T cells activity. Although recent pathological studies have shown that PD-L1 is actively expressed in certain ERα-negative breast cancer, little is known about whether ER signaling regulates PD-L1 gene expression. Here, we investigated the relationship between ERα and PD-L1 in breast cancer. Analysis of Comprehensive Cell Line Encyclopedia (CCLE) data showed that the average mRNA level of PD-L1 in ERα-positive breast cancer cell lines was significantly lower than that in ERα-negative breast cancer cell lines. E2 treatment inhibited PD-L1 mRNA expression in hormone-depleted ERα-positive MCF7 cells. Moreover, ectopic expression of ERα in triple-negative MDA-MB-231 cells reduced PD-L1 mRNA and protein expression. Consistently, analysis of The Cancer Genome Atlas (TCGA) data revealed an inverse correlation between ERα and PD-L1 expression in ERα-positive breast cancer. Taken together, our results identify ERα as a negative regulator of PD-L1 gene transcription in breast cancer cells, suggesting that ERα loss-of-function may facilitate the immune evasion of breast cancer cells via up-regulation of PD-L1.
Insights
Estrogen receptor alpha (ERα) acts as a negative regulator of programmed death-ligand 1 (PD-L1) in breast cancer. Lower ERα levels correlate with higher PD-L1, potentially promoting tumor immune evasion.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Tumor expression of programmed death-ligand 1 (PD-L1) suppresses antitumor immunity by inhibiting T cells via programmed death-1 (PD-1) interaction.
- PD-L1 is expressed in some ERα-negative breast cancers, but the role of estrogen receptor (ER) signaling in regulating PD-L1 is unclear.
Purpose of the Study:
- To investigate the relationship between estrogen receptor alpha (ERα) and PD-L1 expression in breast cancer.
- To determine if ERα signaling influences PD-L1 gene expression.
Main Methods:
- Analysis of Comprehensive Cell Line Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA) datasets.
- Experimental manipulation of ERα and E2 (estrogen) levels in breast cancer cell lines (MCF7 and MDA-MB-231).
- Measurement of PD-L1 mRNA and protein expression.
Main Results:
- PD-L1 mRNA levels were significantly lower in ERα-positive breast cancer cell lines compared to ERα-negative ones.
- E2 treatment reduced PD-L1 mRNA in hormone-depleted ERα-positive MCF7 cells.
- Ectopic ERα expression in ERα-negative MDA-MB-231 cells decreased PD-L1 mRNA and protein levels.
- TCGA data showed an inverse correlation between ERα and PD-L1 expression in ERα-positive breast cancer.
Conclusions:
- Estrogen receptor alpha (ERα) functions as a negative regulator of PD-L1 gene transcription in breast cancer cells.
- Loss of ERα function may enhance breast cancer immune evasion through increased PD-L1 expression.
Related Concept Videos
Negative Regulator Molecules
Master Transcription Regulators
Master Transcription Regulators
Cooperative Binding of Transcription Regulators
Cooperative Binding of Transcription Regulators
Transcriptional Regulation: Riboswitches

